The agency is sitting on a decision to grant full approval for Novavax’s shot, days after top vaccine regulator pushed out.

By Manas Mishra (Reuters) -Shares of U.S. drugmakers fell before the bell on Monday after reports that the Food and Drug ...

An exclusive report by The Wall Street Journal details how Microsoft unveiled OpenAI's unreleased GPT-4 to the world without ...

Commissioner Marty Makary signed off on the plan to push out the agency’s top vaccine official, Peter Marks, in one of his ...

Kennedy Jr., a longtime and visceral critic of pharmaceutical and biotech companies, was nominated by President Trump to be ...

The Town of Tonawanda has formally accused members of its police force of violating the state's Taylor Law by participating ...

Ouster is a high-growth LiDAR technology company with a strong balance sheet, but breakeven is still several years away. Read ...

Ouster's growth potential, competitive edge, and strong financial outlook make it a top buy, with a $27 target. Learn why ...

As the FDA’s top biologics official, Peter Marks oversaw regulation of cell and gene therapies. The departure of Marks and mass layoffs throughout the FDA raise concerns about the agency’s ability to ...

Hailed for his offensive talents, he quickly became the Rangers’ top prospect after the organization drafted him No. 23 ...

Yes, there were some big hits like 'Reacher.' But pricey underperformers like 'Lord of the Rings' and 'Citadel' along with ...

On Monday, Ouster stock earned a positive adjustment to its Relative Strength (RS) Rating, from 80 to 95. IBD's proprietary RS Rating identifies technical performance by using a 1 (worst ...